Gadoteridol use while Breastfeeding

Drugs containing Gadoteridol: Prohance

Gadoteridol Levels and Effects while Breastfeeding

Summary of Use during Lactation

Although early investigators recommended withholding breastfeeding following administration of gadolinium contrast agents, a more recent and much larger study on another agent, gadopentetate, indicated that the amounts of gadolinium excreted into breastmilk are less than 1% of the amount allowed to be given to infants. In addition, because gadolinium contrast agents are poorly absorbed orally, none is likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Additionally, gadoteridol is among the most stable of the gadolinium-containing contrast agents and releases very little free gadolinium, resulting in a low risk of serious toxicity (nephrogenic systemic fibrosis).[1][2] Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[3][4] However, because there is no published experience with gadoteridol during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Possible Effects on Lactation

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Gadopentetate

References

1. European Society of Urogenital Radiology. ESUR guidelines on contrast media. 2012;Version 8.0. http://www.esur.org/guidelines

2. Webb JA, Thomsen HS. Gadolinium contrast media during pregnancy and lactation. Acta Radiol. 2013;54:599-600. PMID: 23966544

3. American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2012;Version 8:79-80.

4. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112:333-40. PMID: 18669732

Gadoteridol Identification

Substance Name

Gadoteridol

CAS Registry Number

112188-16-6

Drug Class

  • Contrast Media
  • Diagnostic Agents

Administrative Information

LactMed Record Number

533

Information from the National Library of Medicine's LactMed Database.

Last Revision Date

2013-09-07

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

See Also...

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web3)